Published: 29 April 2021
Author(s): Trygve S. Hall, Dan Atar
Issue: June 2021
Section: Commentary

Atrial fibrillation (AF) is a highly prevalent condition associated with an increased risk of cardioembolic strokes. Consequently, oral anticoagulation therapy has been established as a cornerstone in the clinical management of patients with AF. However, in patients with an indication for antiplatelet therapy following stent implantation for an acute coronary syndrome (ACS), the optimal antithrombotic strategy in anticoagulated patients remains debated, due to the increased risk of bleeding associated with the use of antiplatelets in dual antithrombotic therapy (DAT) or triple antithrombotic therapy (TAT) regimens.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.